Kanser Hastalarında Bilişsel İşlev Bozukluğu
Özet
Kanser hastalarında hem tedavi sırasında hem de tedavi sonrası remisyon takibinde bilişsel değişiklikler ve bozukluklar meydana gelebilir. Bu, kanserin, komorbid durumların ve uygulanan tedavilerin doğrudan veya dolaylı etkisiyle ilişkili olabilir. Dikkat, bellek ve yönetici işlevler, kanserden etkilenen en sık tanımlanan bilişsel alanlardır. Etkili bir takip ve tanı süreci erken müdahale fırsatlarını artırırken, bireyselleştirilmiş tedavi yaklaşımlarıyla yönetim stratejileri geliştirmek mümkündür. Ancak henüz altın standart bir tanı ve takip yöntemi yoktur. Nöropsikolojik testler (MoCA MMSE gibi), laboratuvar analizleri ve görüntüleme yöntemleri (MRI gibi) yardımcı olabilir. Bu yöntemlerin bir kombinasyonu ile düzenli takip yapılır, hastaların bireysel ihtiyaçlarına uygun stratejilerin geliştirilmesine ve yaşam kalitesinin artmasına olanak tanır.
Cognitive changes and impairments may occur in cancer patients both during treatment and post-treatment remission follow-up. This may be related to the direct or indirect effect of cancer, comorbid conditions, and applied treatments. Attention, memory, and executive functions are the most frequently identified cognitive areas affected by cancer. While an effective follow-up and diagnosis process increases early intervention opportunities, it is possible to develop management strategies with individualized treatment approaches. However, there is no gold standard diagnosis and follow-up method yet. Neuropsychological tests (such as MoCA MMSE), laboratory analyses, and imaging methods (such as MRI) can be helpful. Regular follow-up is performed with a combination of these methods, allowing the development of strategies appropriate to the individual needs of patients and the increase in quality of life.
Referanslar
Dagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study Lancet. 2020;395(10226):785-794. doi:10.1016/S0140-6736(19)32007-0
Peters E, Mendoza Schulz L, Reuss-Borst M. Quality of life after cancer-How the extent of impairment is influenced by patient characteristics. BMC Cancer. 2016;16(1):787. doi:10.1186/s12885-016-2822-z
Lange M, Joly F, Vardy J, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Annals Oncology. 2019;30(12):1925-1940. doi:10.1093/annonc/mdz410
Lange M, Licaj I, Clarisse B, et al. Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey. Cancer Medicine. 2019;8(5):2654-2663. doi:10.1002/cam4.2069
Ganz PA, Kwan L, Castellon SA, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. Journal of the National Cancer Institute. 2013;105(11):791-801. doi:10.1093/jnci/djt073
Nguyen LD, Ehrlich BE. Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases. EMBO Molecular Medicine. 2020;12(6):e12075. doi:10.15252/emmm.202012075
Wefel JS, Lenzi R, Theriault R, et al. ‘Chemobrain’ in breast carcinoma?: a prologue. Cancer. 2004;101(3):466–75. doi: 10.1002/cncr.20393
Weiss MJ. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. Oncologist. 2003;8 Suppl 3:18-29.
Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). 2000;14(1):75-85.
Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788-793. doi:10.1002/cncr.21234
Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Seminars in Clinical Neuropsychiatry. 2003;8(4):201-216.
Staat K, Segatore M. The phenomenon of chemo brain. Clinical Journal of Oncology Nursing. 2005;9(6):713-721. doi:10.1188/05.CJON.713-721
Jean-Pierre P. Management of Cancer-related Cognitive Dysfunction-Conceptualization Challenges and Implications for Clinical Research and Practice. US Oncology. 2010;6:9-12. doi:10.17925/ohr.2010.06.0.9
Millan MJ, Agid Y, Brüne M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery. 2012;11(2):141-168. doi:10.1038/nrd3628
Holohan KN, Von Ah D, McDonald BC, Saykin AJ. Neuroimaging, cancer, and cognition: state of the knowledge. Seminars in Oncology Nursing. 2013;29(4):280-287. doi:10.1016/j.soncn.2013.08.008
Deprez S, Billiet T, Sunaert S, Leemans A. Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review. Brain Imaging and Behavior. 2013;7(4):409-435. doi:10.1007/s11682-012-9220-1
Castel H, Denouel A, Lange M, Tonon MC, Dubois M, Joly F. Biomarkers Associated with Cognitive Impairment in Treated Cancer Patients: Potential Predisposition and Risk Factors. Frontiers in Pharmacology. 2017;8:138. doi:10.3389/fphar.2017.00138
Schagen SB, Klein M, Reijneveld JC, et al. Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. European Journal of Cancer Supplements. 2014;12(1):29-40. doi:10.1016/j.ejcsup.2014.03.003
de Groot M, Douw L, Sizoo EM, et al. Levetiracetam improves verbal memory in high-grade glioma patients. Neuro-Oncology. 2013;15(2):216-223. doi:10.1093/neuonc/nos288
Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Annals of Neurology. 2003;54(4):514-520. doi:10.1002/ana.10712
Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine. 2014;370(8):699-708. doi:10.1056/NEJMoa1308573
Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. Journal of Clinical Oncolgy. 2004;22(1):157-165. doi:10.1200/JCO.2004.05.128
Joly F, Lange M, Dos Santos M, Vaz-Luis I, Di Meglio A. Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors. Cancers (Basel). 2019;11(12):1896. doi:10.3390/cancers11121896
Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA: A Cancer Journal of Clinicians. 2015;65(2):123-138. doi:10.3322/caac.21258
Ahles TA, Root JC. Cognitive Effects of Cancer and Cancer Treatments. Annual Review of Clinical Psychology. 2018;14:425-451. doi:10.1146/annurev-clinpsy-050817-084903
Vardy JL, Dhillon HM, Pond GR, et al. Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. Journal of Clinical Oncology. 2015;33(34):4085-4092. doi:10.1200/JCO.2015.63.0905
Loh KP, Janelsins MC, Mohile SG, et al. Chemotherapy-related cognitive impairment in older patients with cancer. Journal of Geriatric Oncology. 2016;7(4):270-280. doi:10.1016/j.jgo.2016.04.008
Myers JS. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncology Nursing Forum. 2012;39(1):E31-E40. doi:10.1188/12.ONF.E31-E40
Pirl W, Baker KS, Freidman DL, et al. NCCN Guidelines Version 1.2024 Survivorship; 2024.
Goedendorp MM, Knoop H, Gielissen MF, Verhagen CA, Bleijenberg G. The effects of cognitive behavioral therapy for postcancer fatigue on perceived cognitive disabilities and neuropsychological test performance. Journal of Pain and Symptom Management. 2014;47(1):35-44. doi:10.1016/j.jpainsymman.2013.02.014
Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology. 2012;21(2):176-186. doi:10.1002/pon.1878
Ferguson RJ, Sigmon ST, Pritchard AJ, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer. 2016;122(11):1782-1791. doi:10.1002/cncr.29891
Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database of Systemic Reviews. 2008;(3):CD005381. doi:10.1002/14651858.CD005381.pub3
Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. European Journal of Cancer. 2015;51(4):437-450. doi:10.1016/j.ejca.2014.12.017
Treanor CJ, McMenamin UC, O'Neill RF, et al. Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment. Cochrane Database of Systemic Reviews. 2016;2016(8):CD011325 doi:10.1002/14651858.CD011325.pub2
Damholdt MF, Mehlsen M, O'Toole MS, Andreasen RK, Pedersen AD, Zachariae R. Web-based cognitive training for breast cancer survivors with cognitive complaints-a randomized controlled trial. Psychooncology. 2016;25(11):1293-1300. doi:10.1002/pon.4058
Ercoli LM, Petersen L, Hunter AM, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology. 2015;24(11):1360-1367. doi:10.1002/pon.3769
Bray VJ, Dhillon HM, Bell ML, et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. Journal of Clinical Oncology. 2017;35:217-225.
Myers JS. Review complementary and integrative interventions for cancer-related cognitive changes. Asian Pacific Journal of Oncology Nursing. 2015;2(4):215-226. doi:10.4103/2347-5625.162825
Barton DL, Burger K, Novotny PJ, et al. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Supportive Care in Cancer. 2013;21(4):1185-1192. doi:10.1007/s00520-012-1647-9
Liou KT, Root JC, Garland SN, et al. Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial. Cancer. 2020;126(13):3042-3052. doi:10.1002/cncr.32847
Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Review of Anticancer Therapy 2012;12:255-269.
Conklin HM, Khan RB, Reddick WE, et al. Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. Journal of Pediatric Psychology. 2007;32:1127-1139.
Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009;115:2605-2616
Lundorff LE, Jonsson BH, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliative Medicine. 2009;23:731-738.
Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: A phase III randomized placebo-controlled clinical trial. Journal of Clinical Oncology. 2015;33:1653-1659.
Lawrence JA, Griffin L, Balcueva EP, et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. Journal of Cancer Survivorship. 2016;10:176-184.
Cauli O. Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: A Scoping Review. Antioxidants (Basel). 2021;10(7):1116. doi:10.3390/antiox10071116
Qi X, Jha SK, Jha NK, et al. Antioxidants in brain tumors: current therapeutic significance and future prospects. Molecular Cancer. 2022;21(1):204. doi:10.1186/s12943-022-01668-9
Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Critical Reviews in Oncology/Hematology. 2006;57(2):175-182. doi:10.1016/j.critrevonc.2005.06.001
Das A, Ranadive N, Kinra M, Nampoothiri M, Arora D, Mudgal J. An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants. Current Neuropharmacology. 2020;18(9):838-851. doi:10.2174/1570159X18666200221113842
